Telum raises €18M to push phage-derived antimicrobials toward clinic
Spanish biotech Telum Therapeutics has raised €18 million in Series A financing to move its lead antimicrobial programme toward clinical development.
Why it matters: Telum is trying to develop a new class of protein-based antimicrobials for infections where traditional antibiotics are losing ground. Its lead programme targets hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii, a difficult-to-treat Gram-negative pathogen linked to multidrug resistance.
Zoom in: The round was led by AMR Action Fund, with participation from new investor Inveready and existing backers Invivo Partners, CDTI-Innvierte, Clave Capital and Sodena. Telum said the financing should allow it to advance the lead candidate through Phase 1 development and generate early safety and translational data.
How it works: Telum’s platform is built around engineered phage lytic proteins, or enzybiotics. These are enzymes inspired by bacteriophages, viruses that infect bacteria, and are designed to break down the bacterial cell wall.
- The company says it combines metagenomic datasets, synthetic biology, protein engineering and generative AI to design lytic enzymes with improved potency, stability and bacterial targeting. Instead of relying only on naturally occurring phage lysins, Telum says it identifies functional antimicrobial modules from different biological sources and combines enzymatic hydrolysis domains with substrate-recognition domains.
- The goal is to create precision antimicrobial proteins that can kill specific bacterial pathogens externally, including drug-resistant strains, while potentially avoiding some limitations of conventional small-molecule antibiotics.
The pipeline: Telum’s current portfolio also includes two earlier preclinical programmes targeting Gram-positive pathogens: MRSA in prosthetic joint infections and cardiac implantable electronic device infections, and vancomycin-resistant Enterococcus faecium in nosocomial infections.
Backstory: Telum was founded in Navarra, Spain, in 2019 by Roberto Díez, who had worked for more than a decade on antibiotics and phage lytic enzymes, including at CSIC and Rockefeller University in New York.
- The company previously raised €4.1 million in a first financing round in July 2020. At the time, Telum was advancing IKB206, a programme targeting infections caused by multidrug-resistant Escherichia coli, and had indicated plans to begin a first-in-human trial in late 2022.
Yes, but: IKB206 no longer appears in Telum’s public pipeline. A third-party drug database lists IKB206 as discontinued at the preclinical stage.
The bottom line: Telum’s €18 million round gives the Spanish biotech a clearer path into human testing. The bigger question is whether engineered lytic proteins can deliver the combination antimicrobial developers need most: targeted killing, clinical-grade safety and a development path that can survive the economics of antibiotic innovation.
